本次交易完成后，北京金康普将成为公司的控股子公司，纳入合并财务报表范围。本次交易不构成重大 资产重组及重组上市。 本次交易将北京金康普纳入上市公司体系，双方将充分发挥业务上下游的协同效应。上市公司在食品饮 料、保健品领域的配方研发能力与核心竞争力将得到进一步提升，同时更精准地覆盖终端消费品牌，提 高业务附加值；北京金康普可依托上市公司获得天然原料供应保障和全球市场营销体系协同赋能，最终 实现双方优势资源互补、合作共赢的发展格局。 莱茵生物表示，公司控制权变更、发行股份及支付现金购买资产并募集配套资金事项目前处于筹划阶 段，尚存在重大不确定性，敬请广大投资者注意投资风险。 明起停牌。 莱茵生物（002166）12月9日晚间公告，公司于2025年12月8日收到控股股东、实际控制人秦本军的通 知，秦本军正在筹划公司控制权变更事宜。公司股票自2025年12月10日开市起停牌，预计停牌时间不超 过10个交易日。 公告显示，秦本军及公司已与本次交易的主要交易对方广州德福营养投资合伙企业（有限合伙）（简 称"广州德福营养"）、德福金康普控股有限合伙企业、厦门德福金普投资合伙企业（有限合伙）分别签 署了《控制权变更意向协议》 ...

明起停牌。 莱茵生物（002166）12月9日晚间公告，公司于2025年12月8日收到控股股东、实际控制人秦本军的通知，秦本军正在筹划公司控制权变更 事宜。公司股票自2025年12月10日开市起停牌，预计停牌时间不超过10个交易日。 公告显示，秦本军及公司已与本次交易的主要交易对方广州德福营养投资合伙企业（有限合伙）（简称"广州德福营养"）、德福金康普控 股有限合伙企业、厦门德福金普投资合伙企业（有限合伙）分别签署了《控制权变更意向协议》《发行股份购买资产并募集配套资金意向 协议》，协议约定秦本军通过协议转让方式将其所持有的部分公司股份转让给广州德福营养，并签署《表决权放弃协议》，自愿放弃其所 持公司部分股份的表决权。上述事项可能导致公司控股股东及实际控制人发生变更。 同时公司拟向德福金康普控股有限合伙企业和厦门德福金普投资合伙企业（有限合伙）发行股份购买其合计持有的北京金康普食品科技有 限公司（简称"北京金康普"）80%股权，以及向广州德福营养发行股份募集配套资金。 本次交易完成后，北京金康普将成为公司的控股子公司，纳入合并财务报表范围。本次交易不构成重大资产重组及重组上市。 本次交易将北京金康普纳入上市公 ...

Group 1 - Longi Green Energy has decided to terminate its plan for issuing global depositary receipts overseas and listing on the Swiss Stock Exchange, citing stable production and operations as reasons for this cautious decision [1] - Borui Communication plans to acquire a 51% stake in Meijing Technology for 66.49 million yuan to enhance its focus on modern media and digital transformation [2] - Tianyuan Dike's chairman has been placed under detention by the local supervisory authority, but the company assures that its operations remain normal and unaffected [3] Group 2 - Rhine Biotech is planning a change in control and asset acquisition, leading to a suspension of its stock trading starting December 10 [4] - Fosun Pharma's subsidiary has signed a licensing agreement with Pfizer, which includes an upfront payment of 15 million USD and potential milestone payments up to 35 million USD for the development of a GLP-1R agonist [5] - Yongmaotai intends to invest approximately 400 million yuan in a new intelligent manufacturing project for magnesium-aluminum alloy components [6] Group 3 - Huayi Group's subsidiary has been ordered to suspend operations for environmental remediation, which is expected to impact production [7][8] - Boyuan Chemical's subsidiary has commenced trial production of a 1 million tons/year soda ash production line, enhancing its market position [9] - Tiandi Technology plans to invest 3.545 billion yuan in a research center for intelligent mining equipment in Xi'an [10] Group 4 - Daye Co. has a minor stake in Jiangbei Company, which focuses on aerospace products, but its financial impact is limited due to the small shareholding [11] - Xiamen Airport is planning to acquire 100% of its controlling shareholder's subsidiary to adapt to the upcoming changes in airport operations [12] - Zhaoyi Innovation has received approval from the CSRC for its overseas listing of H-shares, planning to issue up to 51.8 million shares [13] Group 5 - Yangfan New Materials' controlling shareholder has been released from detention, allowing normal operations to resume [14] - Tangrenshen reported a decline in pig sales revenue for November, with a 24.05% decrease month-on-month [15][16] - China Merchants Shekou achieved a sales amount of 14.094 billion yuan in November, with cumulative sales reaching 170.166 billion yuan for the year [17] Group 6 - Zhengbang Technology reported a slight increase in pig sales revenue for November, with a 8.55% rise month-on-month [18] - Luoniushan's pig sales revenue increased by 13.57% year-on-year in November, despite a slight decline in monthly sales [19] - Tiankang Bio reported a 1.2% increase in pig sales revenue for November, with a year-to-date decline in total revenue [20] Group 7 - Huitai Medical plans to repurchase shares worth 200 million to 250 million yuan for employee stock ownership plans [21] - Financial Street's major shareholder increased its stake by 703,840 shares, raising its ownership to nearly 15% [22] - Shenzhou Information's major shareholder plans to reduce its stake by up to 3% [23] Group 8 - Yingpais plans to increase its stake in the company by 60 million to 120 million yuan within six months [24] - Jingu Co. intends to repurchase shares worth 30 million to 60 million yuan for employee stock ownership plans [25] - Songcheng Performing Arts plans to repurchase shares worth 100 million to 200 million yuan for capital reduction [26] Group 9 - Bai'ao Intelligent has pre-won contracts for projects totaling 27.5 million yuan, which is expected to positively impact future performance [27] - Heshun Electric has been awarded a procurement project from the State Grid worth 107 million yuan, representing nearly 25% of its projected revenue [28] - Jinggong Technology signed a sales contract worth 729 million yuan, accounting for 42.16% of its expected annual revenue [29] Group 10 - Zhongchao Holdings' subsidiary received an order for high-temperature alloy precision castings worth 51.56 million yuan [30] - Wanma Technology has pre-won multiple projects from the State Grid totaling 59.94 million yuan [31] - ST Weihai, in partnership with a construction institute, won a contract for a smart agriculture project worth 652 million yuan [32] - Chongqing Construction's subsidiary has secured a construction project worth 1.714 billion yuan [33]

Group 1 - The company Rhine Biotech (002166) announced a stock suspension starting December 10 due to plans for a change in control, issuance of shares, and cash payment for asset acquisition, with the suspension expected to last no more than 10 trading days [1][3] - The controlling shareholder Qin Benjun is planning to transfer part of his shares and relinquish voting rights, with the counterparty for the share transfer being Guangzhou Defu Nutrition Investment Partnership [1][3] - Rhine Biotech intends to acquire at least 80% of Beijing Jinkangpu Food Technology Co., Ltd. through a combination of share issuance and cash payment, which will make Beijing Jinkangpu a subsidiary included in the consolidated financial statements [1][3] Group 2 - Beijing Jinkangpu, established in 2004, specializes in the compounding, testing, sales, and technical development and services of food nutrition fortifiers [2][4] - Rhine Biotech's core product is natural sweeteners, indicating a potential synergy with Beijing Jinkangpu's offerings in the food technology sector [2][4]

Core Viewpoint - Rhine Biotech (002166) announced a suspension of its stock trading starting December 10 due to plans for a change in control, issuance of shares, and cash payment for asset acquisition, with the suspension expected to last no more than 10 trading days [1] Group 1: Control Change - The controlling shareholder and actual controller, Qin Benjun, is planning to transfer part of his shares and relinquish voting rights [1] - A "Control Change Intent Agreement" has been signed with the counterparty, Guangzhou Defu Nutrition Investment Partnership (Limited Partnership) [1] Group 2: Acquisition Details - Rhine Biotech intends to acquire at least 80% of Beijing Jinkangpu Food Technology Co., Ltd. through a combination of share issuance and cash payment [1] - Following the transaction, Beijing Jinkangpu will become a subsidiary of Rhine Biotech and will be included in the consolidated financial statements [1] - The transaction is not classified as a major asset restructuring or restructuring listing, but it is expected to constitute a related party transaction [1] Group 3: Company Background - Beijing Jinkangpu, established in 2004, specializes in the compounding, testing, sales, and technical development of food nutrition fortifiers [1] - Rhine Biotech's core products include natural sweeteners [1]

经公司申请，公司股票（证券简称：莱茵生物，证券代码：002166）自2025年12月10日（星期三）开市 时起开始停牌，预计连续停牌时间不超过10个交易日，即在2025年12月24日（星期三）前，公司将按照 《公开发行证券的公司信息披露内容与格式准则第26号—上市公司重大资产重组》的要求披露相关信 息，并申请公司股票复牌。 公司拟以发行股份及支付现金方式购买北京金康普食品科技有限公司（简称"北京金康普"）至少80%股 权，同时向广州德福营养发行股份募集配套资金。本次交易完成后，北京金康普将成为公司的控股子公 司，纳入合并财务报表范围。 格隆汇12月9日丨莱茵生物(002166.SZ)公布，公司于2025年12月8日收到控股股东、实际控制人秦本军 先生的通知，秦本军先生正在筹划公司控制权变更事宜，拟向交易对手方协议转让其持有的部分公司股 份并放弃其持有的部分公司股份表决权。目前相关各方已就该事项签署了《控制权变更意向协议》，具 体交易方案、协议条款等尚需进一步论证和磋商，届时将以各方签订的正式交易协议为准，上述事项可 能导致公司控股股东及实际控制人发生变更。本次权益变动尚需履行协议转让相关程序。 ...

经公司申请，公司股票（证券简称：莱茵生物，证券代码：002166）自2025年12月10日（星期三）开市 时起开始停牌，预计连续停牌时间不超过10个交易日，即在2025年12月24日（星期三）前，公司将按照 《公开发行证券的公司信息披露内容与格式准则第26号—上市公司重大资产重组》的要求披露相关信 息，并申请公司股票复牌。 格隆汇12月9日丨莱茵生物(002166.SZ)公布，公司于2025年12月8日收到控股股东、实际控制人秦本军 先生的通知，秦本军先生正在筹划公司控制权变更事宜，拟向交易对手方协议转让其持有的部分公司股 份并放弃其持有的部分公司股份表决权。目前相关各方已就该事项签署了《控制权变更意向协议》，具 体交易方案、协议条款等尚需进一步论证和磋商，届时将以各方签订的正式交易协议为准，上述事项可 能导致公司控股股东及实际控制人发生变更。本次权益变动尚需履行协议转让相关程序。 公司拟以发行股份及支付现金方式购买北京金康普食品科技有限公司（简称"北京金康普"）至少80%股 权，同时向广州德福营养发行股份募集配套资金。本次交易完成后，北京金康普将成为公司的控股子公 司，纳入合并财务报表范围。 ...

（记者 曾健辉） 截至发稿，莱茵生物市值为65亿元。 每经头条（nbdtoutiao）——处方药变"瘾品"：国内首次报告普瑞巴林滥用致成瘾病例，网络平台暴 露"无病历可购药"漏洞，列管与否尚需科学考量 每经AI快讯，莱茵生物（SZ 002166，收盘价：8.7元）12月9日晚间发布公告称，桂林莱茵生物科技股 份有限公司（以下简称"公司"）于2025 年12 月8 日收到控股股东、实际控制人秦本军先生的通知，秦 本军先生正在筹划公司控制权变更事宜，拟向交易对手方协议转让其持有的部分公司股份并放弃其持有 的部分公司股份表决权。目前相关各方已就该事项签署了《控制权变更意向协议》，具体交易方案、协 议条款等尚需进一步论证和磋商，届时将以各方签订的正式交易协议为准，上述事项可能导致公司控股 股东及实际控制人发生变更。本次权益变动尚需履行协议转让相关程序。经公司申请，公司股票自2025 年12月10日（星期三）开市时起开始停牌，预计连续停牌时间不超过10个交易日，即在2025年12月24日 （星期三）前，公司将按照《公开发行证券的公司信息披露内容与格式准则第26号—上市公司重大资产 重组》的要求披露相关信息，并申请公司股 ...

此外，公司拟以发行股份及支付现金方式购买北京金康普食品科技有限公司(简称"北京金康普")至少 80%股权，同时向广州德福营养发行股份募集配套资金。本次交易完成后，北京金康普将成为公司的控 股子公司，纳入合并财务报表范围。 莱茵生物（002166）(002166.SZ)公告，公司于2025年12月8日收到控股股东、实际控制人秦本军先生的 通知，秦本军先生正在筹划公司控制权变更事宜，拟向交易对手方协议转让其持有的部分公司股份并放 弃其持有的部分公司股份表决权。目前相关各方已就该事项签署了《控制权变更意向协议》。公司股票 自2025年12月10日开市起停牌，预计停牌时间不超过10个交易日。 ...

智通财经APP讯，莱茵生物(002166.SZ)公告，公司于2025年12月8日收到控股股东、实际控制人秦本军 先生的通知，秦本军先生正在筹划公司控制权变更事宜，拟向交易对手方协议转让其持有的部分公司股 份并放弃其持有的部分公司股份表决权。目前相关各方已就该事项签署了《控制权变更意向协议》。公 司股票自2025年12月10日开市起停牌，预计停牌时间不超过10个交易日。 此外，公司拟以发行股份及支付现金方式购买北京金康普食品科技有限公司(简称"北京金康普")至少 80%股权，同时向广州德福营养发行股份募集配套资金。本次交易完成后，北京金康普将成为公司的控 股子公司，纳入合并财务报表范围。 ...